Arcellx Shares Drop 6.2% as Analysts Weigh In on Stock Ratings

Shares of Arcellx, Inc. (NASDAQ: ACLX) experienced a significant decline of 6.2% during mid-day trading on Thursday, falling to a low of $68.57 before ending the session at $68.4050. The trading volume reached 919,670 shares, marking a 40% increase compared to the average session volume of 656,541 shares. This drop follows a previous closing price of $72.94, signaling a noteworthy shift in investor sentiment.

Analysts have recently provided mixed evaluations regarding Arcellx’s stock. Wolfe Research initiated coverage on the company with a “peer perform” rating in a report released on November 18, 2023. Meanwhile, Weiss Ratings maintained a “sell (D-)” rating in a report from October 8, 2023. Conversely, Cantor Fitzgerald reaffirmed a “neutral” rating and set a price target of $88.00 in a report on October 9, 2023. Stifel Nicolaus went further with a “buy” rating and a target price of $129.00 on October 16, 2023, while Citigroup reiterated a “buy” rating on November 24, 2023.

Currently, eight equities research analysts have rated Arcellx’s stock with a “buy” designation, while two analysts issued a “hold” rating and one assigned a “sell” rating. According to MarketBeat.com, the consensus rating for the stock is “Moderate Buy” with an average price target of $115.50.

Recent Earnings Report Highlights

Arcellx recently reported its quarterly earnings on November 5, 2023. The company disclosed an earnings per share (EPS) of ($0.99), which fell short of analysts’ expectations of ($0.96) by $0.03. The firm also reported a negative return on equity of 51.13% and a staggering negative net margin of 607.01%. Revenue for the quarter was $4.95 million, significantly below the consensus estimate of $11.24 million. Analysts predict that Arcellx will post an EPS of ($1.58) for the current fiscal year.

Insider trading activity has also been notable. On November 17, 2023, insider Christopher Heery sold 340 shares at an average price of $90.00, resulting in a total transaction value of $30,600.00. Post-sale, Heery holds 284 shares valued at approximately $25,560, reflecting a 54.49% decrease in ownership. In the last quarter, insiders sold a total of 37,486 shares worth $3,030,736, with company insiders now owning 8.35% of the stock.

Institutional Investor Activity

In recent months, several institutional investors have adjusted their holdings in Arcellx. MAI Capital Management acquired a new stake valued at approximately $26,000 during the third quarter. CWM LLC increased its stake by 267.0%, now owning 345 shares valued at $28,000 after acquiring an additional 251 shares. The State of Wyoming also purchased a new position worth $28,000, while Ramirez Asset Management Inc. and Abich Financial Wealth Management LLC invested $41,000 and $62,000, respectively, in the same quarter. Overall, institutional investors own a substantial 96.03% of Arcellx’s stock.

Founded to develop innovative immunotherapies for patients battling cancer and other serious diseases, Arcellx’s lead product candidate is anitocabtagene autoleucel, currently in phase 2 clinical trials for the treatment of relapsed or refractory multiple myeloma (rrMM). As the company navigates through market fluctuations and earnings challenges, stakeholder attention remains focused on its future developments and strategic direction.